A mouse monoclonal antibody (AN9P1) to keratan sulphate is described. In a competitive-inhibition solution-phase radioimmunoassay employing l25l-labelled intact proteoglycan, it reacts preferentially with keratan sulphate bound to the core protein of adult human articular-cartilage proteoglycan and to a much lesser degree with keratan sulphate purified from this proteoglycan. Proteolytic cleavage of the proteoglycan by pepsin and trypsin has little effect on antibody binding, but treatment with papain decreases binding considerably and more than does treatment with keratanase. An even greater decrease in binding is observed after treatment with alkaline borohydride. A comparison of binding of antibody AN9P1 with that of another previously described monoclonal antibody, 1/20/5-D-4, to keratan sulphate [Caterson, Christner & Baker (1983) J. Biol. Chem. 258,[8848][8849][8850][8851][8852][8853][8854] revealed similar binding characteristics, both showing much diminished binding after papain digestion of proteoglycan and even less with purified skeletal keratan sulphate. Removal of the Fc piece of antibody AN9P1 had no significant effect on the differential binding of divalent F(ab')2 fragment to proteoglycan, to papain-digested proteoglycan and to keratan sulphate, although there was a small decrease in binding to papain-digested proteoglycan. Conversion of the antibody into univalent Fab fragment with removal of the Fc piece resulted in diminished binding to proteoglycan, compared with that observed with IgG, and in enhanced binding to free keratan sulphate and to papaindigested proteoglycan. These results suggest that close proximity of keratan sulphate chains on the core protein of proteoglycans favours preferential reactivity of bivalent antibody with these species through cross-bridging of chains by antibody. Conversely, much decreased binding to keratan sulphate on proteoglycan core-protein fragments and to free keratan sulphate results from a lack of close proximity of keratan sulphate. By using univalent Fab fragment in these assays these differences in binding are minimized by preventing cross-bridging and thereby enhancing detection of smaller fragments without sacrificing too much sensitivity of detection of larger proteoglycan species. The persistent preferential binding of Fab fragment to proteoglycan is probably in part the result of the increased epitope density in the intact molecule compared with keratan sulphate in a more disperse form.
INTRODUCTION
The high-buoyant-density proteoglycans of cartilage matrix display a complex structural organization that changes with age (Roughley & Mort, 1986; Poole, 1986; Webber et al., 1987) . The advent of the use of polyclonal and monoclonal antibodies for the study of these molecules has enabled us to gain further insight into their chemical structures when these are used in conjunction with more traditional biochemical approaches. The use of antibodies now permits us to detect very small amounts of these molecules, to assay them in body fluids and to study biosynthesis, differences in their structural organization, their interaction with other molecules and their distribution and organization in tissues (Wieslander & Heinegard, 1979; Poole et al., 1980a Poole et al., ,b, 1982 Kimura et al., 1981; Buckwalter et al., 1982; Thonar et al., 1982; Ratcliffe et al., 1984; Glant et al., 1986b; Witter et al., 1987; Webber et al., 1987) .
Antibodies have been prepared that react with the hyaluronic acid-binding region (Thonar et al., 1982 ; Ratcliffe & Hardingham, 1983; Stevens et al., 1985; Witter et al., 1987) , with epitopes on the protein core where the glycosaminoglycans chondroitin sulphate and keratan sulphate are attached (Glant et al., 1986a) and with chrondroitin sulphate (Christner et al., 1980; Jenkins et al., 1981; Couchman et al., 1984) and hyaluronic acid once these glycosaminoglycans have been cleaved by eliminases, exposing immunoreactive 4,5-unsaturated glucuronosyl residues at the non-reducing ends. Antibodies have also been prepared that react with keratan sulphate attached to core proteins of both cartilage proteoglycans (Caterson et al., 1983; Zanetti et al., 1985; Glant et al., 1986a) and corneal proteoglycans (Conrad et al., 1982; Fudenburgh et al., 1983; SundarRaj et al., 1985) . Of those that react with the cartilage molecule, it has been reported that these also recognize keratan sulphate, or oligosaccharides thereof, isolated from the corneal keratan sulphate proteoglycan (Caterson et al., 1983; SundarRaj et al., 1985; Zanetti et al., 1985) . There has been one published study demonstrating that these monoclonal antibodies react with purified keratan sulphate that has been isolated from cartilage proteoglycan (Mehmet et al., 1986) . In this case reactivity of antibody 1/20/5-D-4 with skeletal keratan sulphate was shown to be much less than that with * To whom correspondence should be addressed.
Vol. 260 I corneal keratan sulphate, whereas antibodies 1-B-4 and MZ15 showed more similar reactivities. But no studies have been made of the importance of antibody valency in binding to keratan sulphate and whether the Fc piece influences binding in any way. Here we describe a monoclonal antibody AN9Pl that reacts with keratan sulphate of high-buoyant-density cartilage proteoglycans. It resembles another monoclonal antibody to keratan sulphate, 1/20/5-D-4 (Caterson et al., 1983) , in that it reacts well with skeletal keratan sulphate only when it is bound to core protein, in contrast with earlier indications (Thonar et al., 1985) . Also, we show that binding of antibody AN9P1 to keratan sulphate is not enhanced when the Fc part of the immunoglobulin is removed but binding to the keratan sulphate of cartilage proteoglycans is dependent upon the bivalency of the antibody.
MATERIALS AND METHODS Preparation of human cartilage proteoglycans
Source of tissue. Human articular-cartilage proteoglycans were obtained from the distal femoral condyles of fetuses and adults at autopsy, within 12 h of death, from individuals in whom there was no macroscopic evidence of joint trauma, connective-tissue abnormality or arthritic diseases (Roughley et al., 1982) .
Extraction and purification. Proteoglycan monomers were prepared from an Al preparation from which an AlDI preparation ofbuoyant density greater than 1.54 g/ ml was isolated by the methodology described by Roughley et al. (1982) . Adult dog articular-cartilage and rabbit chondrocostal-cartilage proteoglycan were also prepared as AlDI preparations. Swarm rat chondrosarcoma proteoglycan monomers were isolated as a DI preparation (Roughley & White, 1980) . Proteoglycan monomer preparations were dialysed at 4°C, twice against 100 vol. of water, once against 100 vol. of 100 mM-sodium acetate or -potassium acetate, pH 6.0, then exhaustively against water, before being freeze-dried. The dried materials were stored desiccated at 4 'C. Bovine nasal-cartilage proteoglycan monomer (AID 1) was generously donated by Dr. L. C. Rosenberg (Montefiore Hospital and Medical Center, Bronx, NY, U.S.A.). Keratan sulphate proteoglycan isolated from bovine cornea (Axelsson & Heinegaird, 1978) was generously donated by Dr. T. Glant (Glant et al., 1986a Keratanase digestion. Proteoglycan monomer at 10 mg/ml in 80 mM-NaCl/50 mM-Tris/HCl buffer, pH 7.2, containing 1 mM-EDTA, 1 mM-iodoacetic acid, 1 mM-phenylmethanesulphonyl fluoride and 5 4tg of pepstatin/ml, was digested with endo-,/-D-galactosidase (keratanase, from Pseudomonas sp.; Miles Scientific) at a concentration of 1 unit/ml at 37°C for 24 h. Testicular-hyaluronidase digestion. Proteoglycan monomer dissolved at 20 mg/ml in 150 mM-NaCl/0. 1 Msodium acetate buffer, pH 5.0, containing 1 mM-EDTA, 1 mM-iodoacetic acid, 1 mM-phenylmethanesulphonyl fluoride and 5 ,g of pepstatin/ml, was digested with testicular hyaluronidase (bovine type VI; Miles Scientific) at 240 units/mg of proteoglycan at 37°C for 24 h. Endoglycosidase F digestion. Adult human proteoglycan monomer was dissolved at 1 mg/ml in 100 mmsodium phosphate buffer, pH 6.1, containing 50 mm-EDTA, 1 % (v/v) Nonidet P-40, 0.1 % (w/v) SDS and 1 % (v/v) 2-mercaptoethanol. Endoglycosidase F (New England Nuclear, Boston, MA, U.S.A.) was added in the same buffer at 6 units/mg of proteoglycan. After incubation at 37°C for 24 h, the solution was boiled for 3 min to inactivate the enzyme.
Pepsin, papain and trypsin digestion. Proteoglycan monomer was dissolved at 2 mg/ml in 0.2 M-sodium acetate buffer, pH 5.0 (for pepsin digestion), in the same buffer containing 5 mM-EDTA and 5 mM-cysteine (for papain digestion), or in 50 mM-Tris/HCl buffer, pH 7.5 (for trypsin digestion). Papain (2 x crystallized; ICN Pharmaceuticals, Irvine, CA, U.S.A.), pepsin (Worthington Biochemical Corp., Freehold, NJ, U.S.A.) or trypsin [L-tosylphenylalanylchloromethane-('TPCK'-)treated; Worthington Biochemical Corp.] in the appropriate buffer was added at 10 g/mg of proteoglycan, at the start of incubation and again after 4 h. After incubation for a total of 24 h at 37°C, papain was inhibited by the addition of iodoacetamide to a final concentration of 10 mm, pepsin was inhibited by the addition of pepstatin to a final concentration of 10,ug/ml, and trypsin was inhibited by the addition of soya-bean trypsin inhibitor (type II-S; Sigma Chemical Co., St. Louis, MO, U.S.A.) at 10 ,ug/mg of proteoglycan. In all these studies enzymefree controls were also incubated under the conditions described.
Alkaline-borohydride digestion. Alkaline-borohydride digestion (Carlson, 1976 ) was used to release intact 0-linked glycosaminoglycan chains and 0-linked oligosaccharides from the core protein. Proteoglycan monomer (2 mg) was dissolved in 800,1 of 50 mM-NaOH/ 1 MNaBH4, and incubated for 48 h at 45 'C. The solution was then neutralized by addition of 100 % acetic acid.
Purification of keratan sulphate
Preparation of keratan sulphate. Adult (73-year-old) articular-cartilage proteoglycan (116 mg) was dissolved in 0.2 M-Tris/HCl buffer, pH 7.35, at 8 mg/ml. It was digested for 20 h at 37 'C with chondroitin ABC lyase at 1 unit/20 mg of proteoglycan. After dialysis against water to remove oligosaccharides, the solution was concentrated to a total volume of 9 ml with a YM5 membrane (Amicon), and adjusted to 50 mM-NaOH.
NaBH4 was added to 1 M and the solution was incubated at 45 IC for 48 h. The solution was neutralized with acetic acid, and 5 ml was chromatographed on a column (97 cm x 2.5 cm) of Sephacryl S-200 (Pharmacia, Montreal, Quebec, Canada) at a flow rate of 25 ml/h with 400 mM-NaCl/0. 1 M-Tris/HCl buffer, pH 7.5. Frac-tions (5 ml) were monitored for uronic acid, galactose and A214. The initial galactose-containing peak was concentrated to 20 ml with a YCO5 membrane, and 5 ml was desalted on a column (26 cm x 1 cm) of Bio-Gel P-2 (Bio-Rad Laboratories, Richmond, CA, U.S.A.) at a flow rate of 5 ml/h. The column was monitored for A214. A yield of 23 mg of keratan sulphate was obtained, representing approx. 20 % keratan sulphate by weight of proteoglycan. Further analysis revealed a sulphate/ galactose molar ratio of 0.92:1.
Assays for uronic acid, galactose and sulphate. Uronic acid was determined by the carbazole assay (Bitter & Muir, 1962) . Galactose was determined as neutral sugar by the anthrone assay (Dische, 1962) . Sulphate was measured as described by Terho & Hartiala (1971) . Chromatographic analysis on Sepharose CL4B of purified keratan sulphate and proteolytic digests of adult human cartilage proteoglycan Native human adult proteoglycan (1 mg), a pepsin digest (3 mg), a papain digest (4 mg) and purified keratan sulphate (3 mg) were chromatographed on Sepharose CL-4B columns ( 15 cm x 1 cm) in 4 M-guanidinium chloride with 50 M-Tris/HCl buffer, pH 7.3, at a flow rate of 6 ml/h. Fractions were dialysed against 0.2 Msodium acetate buffer, pH 5.5, and analysed by radioimmunoassay with antibody AN9P1. Production, purification and characterization of monoclonal antibody AN9P1
Immunization. Adult human articular cartilage proteoglycan (AID 1) was dissolved at 20 mg/ml in 0.1 Msodium acetate/0.1 M-Tris/HCl buffer, pH 7.3. Eightweek-old female BALB/c mice were injected on day 0 with a total of 120 ,ug of proteoglycan, emulsified in 300 #1 of 50 % (v/v) Freund's complete adjuvant (Difco, Detroit, MI, U.S.A.) in water, and on day 4 with the same amount emulsified in 300 ,1 of 50 % (v/v) Freund's incomplete adjuvant (Difco) in water. Subsequent injections of 120 jug in 300 #tl of 145 mM-NaCl were given on days 7, 29 and 33. A final injection of 200 ,tg in 500 ,ul of 145 mM-NaCl was given 8 weeks later. All injections were administered subcutaneously at multiple sites on the back and limbs, except for the final booster, which was given intraperitoneally.
Hybridoma generation. The BALB/c-mouse-derived plasmacytoma line SP2/0.Ag 14 (Shulman et al., 1978) was used. It was kindly supplied by Dr. A. Fuks of the McGill University Cancer Centre. The culture of these cells and the fusion procedure have been described previously (Rosenberg et al., 1985) . Cells were cloned by limiting dilution. A monoclonal antibody AN9P1 was selected for study. The hybridoma cells were injected into primed BALB/c mice, where they grew as ascites tumours (Rosenberg et al., 1985) . Control ascitic fluid (containing no proteoglycan-specific antibodies) was produced in the same manner by injecting cells of the parent plasmacytoma line. Ascitic fluids were harvested 1-3 weeks after injection, cells were separated by centrifugation at 600 g for 10 min, and fluids were stored at -20 'C.
Immunoglobulin purification. Immunoglobulins were concentrated and partially purified from ascitic fluid by precipitation with an equal volume of saturated (NH4)2SO4 (Tang et al., 1979) . Protein A-Sepharose affinity chromatography, based on the method of Ey et al. (1978) , modified by Watanabe et al. (1981) , was used to isolate monoclonal mouse IgG and to provide an initial indication of immunoglobulin class and subclass. Protein A-Sepharose was obtained from Pharmacia. Briefly, immunoglobulin was dialysed into 0.14 M-phosphate buffer, pH 8.0, and a 500 #1l sample was applied to a Protein A-Sepharose column of 4 ml bed volume equilibrated with this buffer. Unbound material was eluted. Bound immunoglobulin was eluted with 0.1 Msodium citrate buffer, pH 3.0, followed by rapid neutralization with NaOH.
Determination ofmonoclonal IgG subclass. The subclass of the purified AN9P1 IgG was determined as IgG2a by Ouchterlony immunodiffusion in 0.7 % agarose in phosphate-buffered saline (Poole et al., 1980b) , against subclass-specific antisera (Miles Laboratories, Napierville, IL, U.S.A.).
Antibody 1/20/5-D-4. This antibody, which is an IgG1, has been described in earlier work by Caterson et al. (1983) . It was purchased from ICN (Montreal, Quebec, Canada).
Preparation of F(ab')2 and Fab antibody subunits. F(ab')2 fragment was prepared from antibody AN9PI, which is an IgG2a, by digestion with pepsin as described by Parham (1983) . Fab fragment was prepared from antibody AN9P1 by digestion of immunoglobulin with papain as described by Porter (1959) . F(ab')2 and Fab fragments were separated from undigested IgG and Fc fragments by chromatography of the digest on an affinity column of Protein A-Sepharose as described above. Immunoassays E.l.i.s.a. This was used for identifying antibody in hybridoma cultures. It was performed with adult human articular-cartilage proteoglycan digested with chondroitin ABC lyase in 0.1 M-Tris/acetate buffer, pH 7.3 , diluted in 0.1 M-sodium carbonate buffer, pH 9.0, and bound to 96-well Immulon plates (Dynatech, South Windham, ME, U.S.A.) at a concentration of 2.5,ug/well. The binding and assay were conducted as previously described with the use of hyperimmune IgG (from a pig immunized with mouse IgG) coupled to alkaline phosphatase.
Radioimmunoassay. Human proteoglycan monomer was iodinated by using the chloramine-T method (Sonada & Schlamowitz, 1970) . A 100 ,1 portion of a 1 mg/ml proteoglycan solution in 150 mM-NaCl/50 mM-Tris/HCI buffer, pH 7.5, was combined in a glass test tube with 0.25 mCi of Na121I (New England Nuclear) in 5 #1. Then 10 ,tl of chloramine-T (600 /ag/ml) was added, the tube was capped, and the solution was gently vortex-mixed for exactly 2 min. Then 100 ,1 of sodium metabisulphite (1.2 mg/ml) and 200 ,1 of NaI (10 mg/ml) were added. lodinated proteoglycan was separated from free I2 by chromatography on a Sephadex G-25 (Pharmacia) column (10 ml bed volume) equilibrated with iodination buffer. Void-volume fractions containing greater than 40000 c.p.m./10,ul were pooled for use in the radioimmunoassay.
For all radioimmunoassays, other than those dealing
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with comparative binding of antibody IgG, F(ab')2 fragment and Fab fragment to keratan sulphate, which are described in Fig. 3 and (Ey et al., 1978) , a buffer pH of 8.1, at which all mouse IgG subclasses are bound, was used. Antibodies were serially diluted in radioimmunoassay buffer to give approx. 50 % o of the total binding of radiolabelled proteoglycan, and 100 gl of each dilution (in duplicate) was then combined with 100 II of '251-labelled proteoglycan antigen (10000 c.p.m.) and incubated at room temperature for 90 min. Then 50,l of a 10 % (w/v) suspension of heat-and formalin-killed Protein Abearing Staphylococcus aureus (Zymed; Cedarlane Laboratories, Hornby, Ont., Canada) was added, and the mixture was incubated at room temperature for 20 min. Then 1 ml ofbuffer was added and the suspension was centrifuged at 4000 g for 20 min at 4 'C. The supernatant was discarded and the radioactivity of the pellet was counted to determine bound radioactivity. The radioimmunoassay procedure used in the studies reported in Fig. 3 and Table 4 , where binding of IgG2a, F(ab')2 fragment and Fab fragment were compared, employed a triple-antibody method. To the radiolabelled proteoglycan (approx. 10000 c.p.m. per tube) in 150,1l of radioimmunoassay buffer (10 mM-sodium/potassium phosphate buffer, pH 7.2, containing 147 mM-NaCl, 0.05 0 NaN3 and 0.2 % radioimmunoassay-grade bovine serum albumin) is added 50,I of the sample to be assayed (standard or unknown) in radioimmunoassay buffer and 50 ,1 of antibody to keratan sulphate as IgG or F(ab')2 fragment or Fab fragment diluted in radioimmunoassay buffer to give approx. 50 % of maximal binding of 125I-labelled proteoglycan. The mixture is incubated for 1 h at 37 'C. Then 25 ,1 of a hyperimmune rabbit antiserum to mouse IgG (Cappel) diluted 1/16 in radioimmunoassay buffer is added and the incubation at 37 'C is continued for 1 h. Then 25 #1 of non-immune rabbit serum (diluted 1/ 16 in radioimmunoassay buffer) is added followed by 100 dzl of an (NH4)2S04-concentrated preparation of pig immunoglobulin to rabbit F(ab') fragment (prepared from a hyperimmune serum as described by Poole et al., 1985) . After overnight incubation for 18 h at 4 'C, 1 ml of radioimmunoassay buffer was added, the assay tubes were centrifuged and the radioactivities of the pellets were counted. Assays were performed in tripicate. 
RESULTS AND DISCUSSION Binding of antibody AN9P1 to cartilage proteoglycans
Effects of enzymic and chemical treatments of proteoglycan on immunoreactivity and comparison with antibody 5D4. A comparison of binding of antibody AN9Pl to different proteoglycans was made by determining the amount of proteoglycan required to achieve 5000 inhibition of binding to radiolabelled adult human cartilage proteoglycan (Table 1) . Most binding was seen with adult human, rabbit and dog articular-cartilage proteoglycans and with bovine corneal keratan sulphate. Less binding was observed with bovine nasal-cartilage proteoglycan and even less with fetal human cartilage proteoglycan. No binding was seen with rat chondrosarcoma proteoglycan, since there was no inhibition with up to 30 ,ug of proteoglycan/ml. These observations indicated that the epitope recognized by this antibody was most common in proteoglycans of adult articular cartilages of different species, deficient in the fetus and absent from the rat chondrosarcoma. However, the epitope was present on the keratan sulphate-containing proteoglycan isolated from the bovine cornea. This observation, combined with the fact that keratan sulphate is deficient in or absent from cartilage proteoglycans isolated from fetal human cartilage and most commonly found in adult human cartilage (Roughley & White, 1980) , and is absent from the rat chondrosarcoma (Choi et al., 1971; Oegema et al., 1975) , suggested that this antibody reacted with keratan sulphate and resembled antibody 1/20/5-D-4 described by Caterson et al. (1983) .
Adult human cartilage proteoglycan was subjected to various enzymic and chemical treatments to characterize antibody binding further. The molecular sizes of some of these degradation products were analysed by chromatography on Sepharose CL-4B (Fig. 1) (Roughley, 1978) , there is a considerable decrease in binding. The greatest decrease was seen after alkalineborohydride treatment, which removes 0-linked oligosaccharides, keratan sulphate and chondroitin sulphate from core protein and cleaves core protein (Lohmander et al., 1980) . The observation that keratanase produced a significant but lesser decrease in binding indicated that the epitope may reside on keratan sulphate. The limited decrease in reactivity after keratanase digestion may reflect the continued reactivity ofkeratan sulphate 'stubs' left attached to core protein.
The decrease in binding observed with papain and alkaline-borohydride treatments also indicated that antibody binding to cartilage proteoglycan may be dependent upon the close proximity of keratan sulphate chains that results when they are bound to the core protein of the proteoglycan. More detailed studies were therefore made of antibody binding to adult human articular-cartilage proteoglycan after some of these treatments; binding to purified keratan sulphate was also studied. Earlier work on monoclonal antibody 1/20/5-D-4, which reacts with keratan sulphate of skeletal and non-skeletal origin, indicates that this antibody reacts equally well with free skeletal keratan sulphate as with keratan sulphate bound to cartilage proteoglycan, although only corneal keratan sulphate and trypsin-digest fragments of cartilage proteoglycans were studied (Caterson et al., 1983) . For this reason, and to establish the similarity of antibody AN9Pl to antibody 1/20/5-D-4, we decided to compare the binding of antibody 1/20/5-D-4 with that of AN9Pl. These results are shown in Fig. 2 . It can be seen that both antibodies displayed very similar inhibition profiles with all proteoglycan preparations, and a much diminished reaction after papain cleavage. Moreover, both antibodies reacted with purified keratan sulphate but to a much lesser degree than with intact proteoglycan. The decreased binding was similar to that observed after treatment of proteoglycan with alkaline borohydride, which frees keratan sulphate from core protein. Table 3 shows the amounts required to achieve 50 % inhibition of binding for each antibody.
Our results clearly demonstrate in this radioimmunoassay that both antibody AN9P1 and antibody 1/20/5-D-4 react with skeletal keratan sulphate but that binding is considerably enhanced when keratan sulphate is part of a cluster of chains attached to core protein.
Dependence of antibody binding on bivalency. The indications of antibody binding being dependent upon binding of keratan sulphate to core protein raised the question whether binding was also antibody-valencydependent and modified by removal of the Fc piece. In Fig. 3 binding of AN9P1 antibody IgG and F(ab')2 and Fab subunits to adult human articular-cartilage proteoglycan, to papain-digested proteoglycan and to purified keratan sulphate are compared. In Table 4 are shown the amounts of proteoglycan, papain-digested proteoglycan and keratan sulphate required to achieve 50 % inhibition of binding. The relative amounts are also indicated to permit a comparison of binding for each set of assays with IgG, F(ab')2 fragment or Fab fragment. Removal of the Fc piece alone leaving bivalent F(ab')2 fragment results in relatively little change in absolute and relative binding to proteoglycan and to keratan sulphate, indicating that the Fc piece does not influence binding of the Fab arms to epitopes. The binding to papain-digested fragments of proteoglycan does, however, show a small decrease. Conversion of antibody into univalent Fab with papain also results in removal of the Fc piece, but now binding to proteoglycan is decreased whereas binding to papain-digested proteoglycan and particularly to free keratan sulphate is increased compared with that of IgG.
These observations indicate that, when intact radioVol. 260 labelled proteoglycan is used in the assay, the bivalent antibody preferentially cross-bridges adjacent keratan sulphate chains where these are present on proteoglycan core protein, leading to preferential binding to 'clusters' of keratan sulphate rather than to one or two chains' of keratan sulphate attached to small fragments of core protein produced by papain digestion (Roughley, 1978) or to single keratan sulphate chains. more disperse form after core protein has been cleaved. The diminished slope of the inhibition curves for papaindigested proteoglycan (Fig. 3 ) compared with similar curves for keratan sulphate and intact proteoglycan also suggests a difference in the conformation of keratan sulphate on papain fragments with a decrese in reactivity with antibody. The further decrease in binding observed after alkaline-borohydride treatment to release free keratan sulphate from core protein would also be expected to result from destruction of clusters of keratan sulphate on papain fragments with a decrease in reactivity after papain cleavage, as suggested by the chromatographic data shown in Fig. 1 . The possibility remains, however, that alkaline-borohydride treatment may lead to some desulphation of the keratan sulphate chain, and loss of sulphate might be expected to affect antibody reactivity. It has been shown that some of these monoclonal antibodies to keratan sulphate, including 1 /20/5-D-4, bind to oversulphated keratan sulphate hexasaccharides (Mehmet et al., 1986 immunoassay of this glycosaminoglycan with antibodies of this kind. Since tissues and body fluids commonly contain smaller proteoglycan fragments produced by degradation (Witter et al., 1987) , the use of such assays employing univalent Fab fragment should represent a significant improvement on existing assays.
